A carregar...
Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer
Background: Alectinib is a new standard treatment for treatment-naïve anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC); however, resistance ultimately develops in almost all patients, and data regarding the efficiency of ceritinib for such patients are insufficient. Patie...
Na minha lista:
| Publicado no: | In Vivo |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
International Institute of Anticancer Research
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6365750/ https://ncbi.nlm.nih.gov/pubmed/30348720 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.11418 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|